glp-1 for fibromyalgia GLP-1s May Ease Symptom Burden in Patients With GLP-1 and migraine, fibromyalgia?

Revenue uplift: USD 12,000-18,000 million

Experts say that slowdown could make alcohol less satisfying and possibly less addictive

Both companies make constant efforts to increase insurance coverage of GLP-1 drugs for obesity.(Source: In April 2026 , Zealand Pharma A/S declared that Boehringer Ingelheim reported positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide met the co-primary endpoints utilizing both the efficacy and treatment-regimen estimands.(Source: Segments Covered in the Report By Product Type GLP-1 Receptor Agonists Semaglutide Liraglutide Dulaglutide Exenatide Lixisenatide Tirzepatide (Dual GIP/GLP-1 Agonist) Other GLP-1-based Therapies Oral GLP-1 Therapies Injectable GLP-1 Therapies By Route of Administration Injectable Once Daily Once Weekly Oral By Indication Type 2 Diabetes Mellitus Obesity & Weight Management Cardiovascular Risk Reduction Non-Alcoholic Steatohepatitis (NASH)/MASH Chronic Kidney Disease (CKD) Other Metabolic Disorders By Drug Class Short-acting GLP-1 Agonists Long-acting GLP-1 Agonists Dual Incretin Agonists Triple Agonists (Pipeline) By Di stribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By End User Hospitals Specialty Clinics Homecare Settings Ambulatory Care Centers By Age Group Adults Geriatric Pediatric By Payer Type Public Insurance Private Insurance By Region North America Latin America Europe Asia-pacific Middle and East Africa For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at [email protected] Frequently Asked Questions Answer : The GLP-1 market size is expected to increase from USD 58.40 billion in 2025 to USD 212.73 billion by 2035

While they have demonstrated some anti-inflammatory effects in research settings, newer agents generally produce greater weight loss and may therefore have more pronounced effects on inflammation-related markers